Top 5 Stock Picks of Benjamin Smith’s Laurion Capital Management

3. Viatris Inc. (NASDAQ:VTRS)

Laurion Capital Management’s Stake Value: $457.2 million
Percentage of Laurion Capital Management’s 13F Portfolio: 1.92%
Number of Hedge Fund Holders: 53

Formed through the merger of Mylan and Upjohn, a division of Pfizer Inc. (NYSE:PFE) in late 2020, Viatris Inc. (NASDAQ:VTRS) is a healthcare company that sells a variety of medicines, generics, and over-the-counter (OTC) drugs under the Xanax, Lipitor and Viagra brands.

As of Q3 2021, Laurion Capital Management owned over 33.7 million shares in Viatris Inc. (NASDAQ: VTRS) with an estimated market value of $457.2 million.

Of the 873 elite funds being tracked by Insider Monkey, 53 held stakes in Viatris Inc. (NASDAQ:VTRS) at the end of the second quarter, down from 58 in the preceding quarter. James Flynn of Deerfield Management is one of the leading shareholders in the company.

On November 16, Viatris Inc. (NASDAQ:VTRS) launched its new interchangeable insulin biosimilar drug, Semglee, in both, branded and unbranded formats. According to Bernstein analyst Ronny Gal, Viatris Inc. (NASDAQ:VTRS) effectively provided payers with the option to choose between a high price, high rebate product, or another that carries a lower price and features a lower rebate.